SPOTLIGHT -
Amir H. Lebastchi, MD, provides insights into the current prostate cancer landscape, emphasizing the importance of prostate cancer screening and early detection.
Studies explore resistance to hormone therapy in prostate cancer
“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Receipt of hormone therapy is lacking among Black men with prostate cancer
Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.
Dr. Laviana on decisional regret after prostate cancer treatment
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
NCCN awards funding to 4 advanced prostate cancer research projects
The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.
Prostate Cancer Treatment: Incorporating Micronized Abiraterone into Clinical Practice
In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.